KAMADA LTD. | Sales 2024 * | 573M 153M 57.34B | Sales 2025 * | 706M 188M 70.6B | Capitalization | 1.13B 301M 113B |
|---|---|---|---|---|---|
| Net income 2024 * | 46M 12.27M 4.6B | Net income 2025 * | 84M 22.41M 8.4B | EV / Sales 2024 * | 1.96 x |
| Net cash position 2024 * | - 0 0 | Net cash position 2025 * | - 0 0 | EV / Sales 2025 * | 1.6 x |
| P/E ratio 2024 * |
-
| P/E ratio 2025 * |
-
| Employees | - |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 54.25% |
More Fundamentals
* Assessed data
More news
Latest transcript on Kamada Ltd.
More press releases
| Managers | Title | Age | Since |
|---|---|---|---|
Amir London
CEO | Chief Executive Officer | 55 | 13-12-08 |
David Tsur
FOU | Founder | 73 | 90-12-12 |
Chaime Orlev
DFI | Director of Finance/CFO | 53 | 17-12-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Ishay Davidi
BRD | Director/Board Member | 62 | 19-12-23 |
Leon Recanati
BRD | Director/Board Member | 76 | 05-04-30 |
David Tsur
FOU | Founder | 73 | 90-12-12 |
Kamada Ltd is Israel based company, focused on plasma-derived protein therapeutics with a commercial product portfolio and a late-stage product pipeline. The Company uses its proprietary platform technology and know-how for the extraction and purification of proteins from human plasma to produce Alpha-1 Antitrypsin (AAT) in a highly-purified, liquid form, as well as other plasma-derived Immune globulins.
Sector
Pharmaceuticals
Calendar
2024-05-13
- Q1 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -3.92% | 88.12B | |
| +4.34% | 40.6B | |
| -23.95% | 28.81B | |
| +51.39% | 24.35B | |
| -5.09% | 17.5B | |
| -32.11% | 13.54B | |
| -5.10% | 13.52B | |
| -14.91% | 12.09B | |
| -4.79% | 7.88B |
